Axsome Therapeutics (AXSM) Finished Goods (2022 - 2026)

Axsome Therapeutics has disclosed Finished Goods across 5 years of filings, most recently posting $15.9 million for Q1 2026.

• Finished Goods for Q1 2026 came in at $15.9 million, up 77.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.9 million (up 77.28% YoY), and the FY2025 annual result was $11.3 million, up 25.53% from the prior year.
• Finished Goods came in at $15.9 million for Q1 2026 at Axsome Therapeutics, up from $11.3 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $15.9 million in Q1 2026 to a low of $1.6 million in Q4 2022.
• The 5-year median for Finished Goods is $9.0 million (2025), against an average of $8.7 million.
• Across the five-year window, Finished Goods surged 506.48% in 2023 and fell 12.0% in 2025, its largest moves.
• Axsome Therapeutics' Finished Goods stood at $1.6 million in 2022, then soared by 506.48% to $9.6 million in 2023, then retreated by 6.81% to $9.0 million in 2024, then gained by 25.53% to $11.3 million in 2025, then soared by 40.85% to $15.9 million in 2026.
• The last three Finished Goods figures came in at $15.9 million (Q1 2026), $11.3 million (Q4 2025), and $10.3 million (Q3 2025), per Business Quant data.